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Dendritic Cells Charged with Apoptotic Tumor Cells Induce
Long-Lived Protective CD4ⴙ and CD8ⴙ T Cell Immunity
against B16 Melanoma1
Romina S. Goldszmid,*† Juliana Idoyaga,† Alicia I. Bravo,‡ Ralph Steinman,2§ José Mordoh,*
and Rosa Wainstok2†

M

elanoma is the cancer with the fastest increasing incidence (1), and survival of patients with distant metastases is generally ⬍1 year. With increased understanding of the requirements for initiating immunity, dendritic cells
(DCs)3 have become attractive vectors for immunotherapy of this
and other cancers (2–9). DCs are proving to be effective in initiating and expanding immune responses in humans (10, 11), providing a rationale for their use as adjuvants for active immunization against melanoma (12–16). Different strategies have been
developed to load DCs with tumor Ags, including MHC-restricted
synthetic peptides derived from the Ag (12–17), tumor RNA (18,
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19), tumor lysates (20), tumor-derived exosomes (21), and dying
tumor cells (22–26); these have been assessed in preclinical models and, in some cases, clinical trials (12–26). Tumor cells (dying
cells or Ab-coated tumor cells) are of interest as an antigenic
source, because the DCs would have the potential to present a
broad range of tumor-associated Ags and on both MHC class I and
II products regardless of the MHC haplotype of the patient
(27–30).
To test whether combined CD4⫹ and CD8⫹ long term immunity
could be elicited by DCs loaded with tumor cells, we have conducted preclinical analyses to immunize mice with DCs previously
exposed to apoptotic melanoma cells ex vivo. There are already
some examples, using DCs bearing defined tumor Ag or tumor
cells engineered to secrete GM-CSF, where T cell-based resistance
to melanoma has been achieved in animals (31–33), but there is no
precedent for the induction of combined MHC I- and II-restricted
immunity in vivo with DCs loaded with tumor cells. We will show
that DCs, after phagocytosis of apoptotic tumor cells, elicit longlived combined CD4⫹ and CD8⫹ immunity against the MHC class
I low B16 murine melanoma.

Materials and Methods
Animals and cell lines
Six- to 8-wk-old male C57BL/6 (HH-2b, CD45.2⫹) mice were obtained
from the Facultad de Ciencias Veterinarias, University of La Plata (Buenos
Aires, Argentina) and from Taconic Farms (Germantown, NY), and
CD45.1⫹ B6.SJL-Ptprc were obtained from Taconic Farms. Mice were
maintained in pathogen-free conditions, and studies were performed in
accordance with local ethical guidelines. B16 (HH-2b) is a poorly immunogenic murine melanoma of spontaneous origin (34). The B16-F1 line (a
gift from Dr. A. Vecchi, Istituto Mario Negri, Milan, Italy) was maintained
in culture in DMEM (Sigma-Aldrich, St. Louis, MO) supplemented with
10% heat-inactivated FCS (Natocor, Córdoba, Argentina), 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin (Life Technologies,
0022-1767/03/$02.00
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Dendritic cells (DCs) are potent APCs and attractive vectors for cancer immunotherapy. Using the B16 melanoma, a poorly
immunogenic experimental tumor that expresses low levels of MHC class I products, we investigated whether DCs loaded ex vivo
with apoptotic tumor cells could elicit combined CD4ⴙ and CD8ⴙ T cell dependent, long term immunity following injection into
mice. The bone marrow-derived DCs underwent maturation during overnight coculture with apoptotic melanoma cells. Following
injection, DCs migrated to the draining lymph nodes comparably to control DCs at a level corresponding to ⬃0.5% of the injected
inoculum. Mice vaccinated with tumor-loaded DCs were protected against an intracutaneous challenge with B16, with 80% of the
mice remaining tumor-free 12 wk after challenge. CD4ⴙ and CD8ⴙ T cells were efficiently primed in vaccinated animals, as
evidenced by IFN-␥ secretion after in vitro stimulation with DCs loaded with apoptotic B16 or DCs pulsed with the naturally
expressed melanoma Ag, tyrosinase-related protein 2. In addition, B16 melanoma cells were recognized by immune CD8ⴙ T cells
in vitro, and cytolytic activity against tyrosinase-related protein 2180 –188-pulsed target cells was observed in vivo. When either
CD4ⴙ or CD8ⴙ T cells were depleted at the time of challenge, the protection was completely abrogated. Mice receiving a tumor
challenge 10 wk after vaccination were also protected, consistent with the induction of tumor-specific memory. Therefore, DCs
loaded with cells undergoing apoptotic death can prime melanoma-specific helper and CTLs and provide long term protection
against a poorly immunogenic tumor in mice. The Journal of Immunology, 2003, 171: 5940 –5947.
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Gaithersburg, MD). The EL-4 thymoma (American Type Culture Collection, Manassas, VA) was used as a control tumor. Cell lines were periodically tested to be mycoplasm-free.

Abs and reagents
We purchased anti-CD16/32, FITC-conjugated anti-CD86, I-Ab, rat IgG,
mouse IgG, PE-anti-CD11c, biotinylated anti-CD45.2, and allophycocyanin-streptavidin (all from BD Biosciences, Mountain View, CA); anti-CD8
and CD4 MACS microbeads (Miltenyi Biotec, Auburn, CA); CFSE (Molecular Probes, Eugene, OR); and ACK buffer (BioSource International,
Camarillo, CA).

Induction and detection of apoptosis and necrosis

Generation of bone marrow-derived DCs and culture with
apoptotic cells
As previously described (35), bone marrow cells were harvested from femurs and tibias of normal C57BL/6 mice and washed with PBS. Cells were
resuspended in RPMI 1640 (Sigma-Aldrich) supplemented with 10% heatinactivated FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 20 g/ml gentamicin (Life Technologies), 50 M 2-ME (SigmaAldrich), and 10% supernatant from CHO cells transfected with the
plasmid pCDNA3 containing the recombinant mouse GM-CSF gene (the
pCDNA3-rmGM-CSF plasmid was provided by Dr. O. Burrone, International Center for Genetic Engineering and Biotechnology, Trieste, Italy)
and cultured in 100-mm diameter plates. On day 3 the cells were refed with
fresh medium. On day 5 of culture immature DCs were harvested and used
for in vitro phenotypic analysis and for coculture with apoptotic cells
(Apo). For coculture, 2 ⫻ 105 DCs were incubated with Apo at a 1/1 ratio
for 24 h, washed twice with PBS, and used for vaccination. Coculture with
necrotic cells or syngeneic splenocytes was performed at a 1/1 ratio.

Phagocytosis of irradiated B16 melanoma cells
After irradiation, apoptotic B16 cells were dyed red using PKH26-GL (Sigma-Aldrich) and cocultured with immature DCs that were dyed green with
PKH67-GL (Sigma-Aldrich) at a 1/1 ratio. After 24 h, flow cytometric
analysis was performed, and phagocytosis of Apo was defined by the percentage of double-positive cells. Alternatively, phagocytosis was observed
by confocal microscopy (LSM 510; Zeiss, New York, NY).

Surface phenotype and in vivo migration of DCs
The surface phenotype of bone marrow-derived DCs was analyzed before
and after coculture with apoptotic tumor cells. DCs were double-stained
with PE-conjugated anti-CD11c and FITC-conjugated anti-CD86 or antiMHC II (I-Ab). B6 bone marrow-derived DCs (CD45.2⫹) with and without
previous coculture with apoptotic B16 were injected s.c. into CD45.1⫹
recipient mice, and draining lymph nodes were removed 24 h later. Singlecell suspensions were prepared with 400 U/ml collagenase (Roche, Indianapolis, IN) for 25 min. Cells were then incubated with PE-conjugated
anti-CD11c, allophycocyanin-conjugated anti-CD45.2, and FITC-conjugated anti-CD86 or MHC II. Flow cytometric data were analyzed with
FlowJo (Tree Star software, San Carlos, CA).

Vaccination of mice
Mice were injected s.c. with 2 ⫻ 105 DCs cocultured with Apo (DC-Apo),
DCs alone, Apo alone, mixtures of DCs plus Apo without previous coculture (DC ⫹ Apo), DCs cocultured with necrotic cells (DC-Nec), necrotic
cells alone (Nec), DCs cocultured with apoptotic syngeneic splenocytes
(DC-Spleen), or vehicle (PBS) weekly for 4 wk. One week after the last
injection, mice received a tumor challenge with 1.3 ⫻ 104 live B16 cells.
Animals were monitored for tumor growth every other day by palpation,
and diameters were measured using a Vernier caliper. Tumor-bearing animals were sacrificed when the tumors displayed severe ulceration or

reached a size of 250 mm2. For evaluation of immunological memory,
mice were challenged 10 wk after the last vaccination. In the case of tumorfree animals, experiments were terminated 12 wk after tumor challenge, and
autopsies were performed. All experiments included 10–13 mice/group.

In vivo depletion of CD4⫹ and CD8⫹ T lymphocytes
Mice immunized as described were injected with murine ascites containing
1 mg of rat monoclonal anti-CD4 (clone GK 1.5) or anti-CD8 (clone 536.72; hybridomas were provided by Dr. A. Vecchi). Three consecutive
injections were performed i.v. on the day before tumor challenge, followed
by two i.p. injections on the day of and the day after tumor challenge.
Control experiments were performed by injecting the same amount of standard rat IgG (Sigma-Aldrich). Depletion of CD4⫹ and CD8⫹ T cells from
spleen was monitored using anti-CD4 and anti-CD8 mAb.

IFN-␥ production by CD4⫹ and CD8⫹ T cells
Four weeks after vaccination, CD4⫹ and CD8⫹ T cells were isolated from
spleen of vaccinated or control mice using MACS microbeads. Purified
CD4⫹ or CD8⫹ T cells were subsequently cocultured in 96-well, flatbottom microtiter plates (3 ⫻ 105 cells/well) in the presence of B16 cells,
DC-Apo, or DCs that had been pretreated with tyrosinase-related protein 2
(TRP2)180 –188 peptide (SVYDFFVWL; a gift from Dr. A. Kalergis, Rockefeller University, New York, NY) or OVA (SIINFEKL) as a control peptide (1 h 37°C, 1 M) for 48 h in Click’s medium containing 0.75% mouse
serum. The titers of IFN-␥ in the culture supernatants were determined by
ELISA (OptEIA kit; BD PharMingen) according to the manufacturer’s
protocol.

In vivo cytotoxicity assay
C57BL/6 splenocytes were divided into two populations and labeled with
either a high concentration (5 M) or a low concentration (0.5 M) of
CFSE for 10 min at 37°C, then washed twice with PBS containing 0.1%
BSA. CFSEhigh cells were pulsed with 1 M TRP2180 –188 peptide, while
CFSElow remained nonpulsed. After washing, CFSEhigh cells were mixed
with equal numbers of CFSElow cells, and 107 or 5 ⫻ 106 of this cell
suspension was injected i.v. into DC-Apo- or DC-vaccinated mice. Spleens
and lymph nodes from recipient mice were taken 10 h later for flow cytometric analysis. In vivo killing was indicated by loss of CFSEhigh peptide-pulsed cells relative to CFSElow nonpulsed cells. The percentage of
specific lysis was calculated according to the formula: (1 ⫺ (ratio
unprimed/ratio primed) ⫻ 100), where ratio unprimed ⫽ % CFSElow/CFSEhigh cells remaining in control mice, and ratio primed ⫽ % CFSElow/
CFSEhigh cells remaining in vaccinated mice.

Statistical analysis
Statistical analyses were performed using the Wilcoxon rank test.

Results
Apoptotic B16 melanoma cells are efficiently phagocytosed by DCs
Whole tumor cells are an advantageous source of Ags for DC
vaccination because they provide a wide range of tumor Ags that
can be processed onto both MHC class I and class II products by
DCs. To induce apoptosis, B16 cells were irradiated (70 Gy) and
cultured for 48 h. The tumor cells then failed to grow in culture and
could not induce tumors in mice at high doses (106 cells). Apoptosis was documented by annexin V/PI staining (Fig. 1). After
48 h, cultured unirradiated cells contained 10 –12% early apoptotic
cells characterized by annexin V⫹/PI⫺ staining (Fig. 1A, lower
right). In contrast, 70 – 80% of irradiated cultured tumor cells had
undergone early apoptotic death (Fig. 1B). Twelve to 19% of the
cells displayed annexin V⫹/PI⫹ staining, indicating secondary necrosis in both unirradiated and irradiated cultures (Fig. 1, A and B,
upper right). Eighty percent of freeze/thawed necrotic cells displayed annexin V⫹/PI⫹ staining (data not shown). Then PKH67
green-labeled DCs (Fig. 1C) were cultured with PKH26 red-labeled, apoptotic tumor cells (Fig. 1D) for 24 h, and phagocytosis
was documented by the percentage of double-positive cells. At
37°C, ⬎40% of immature DCs phagocytosed apoptotic material
(Fig. 1E), and this was confirmed by confocal fluorescence microscopy and electron microscopy (data not shown). Freeze/
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After reaching 70 – 80% confluence, tumor cells were harvested with 0.5
mM EDTA, washed with PBS (HyClone, Logan, UT), and resuspended for
irradiation (70 Gy, linear accelerator; Siemens, New York, NY). Irradiated
cells were washed twice, cultured for 48 h, and harvested by pipetting for
coculture with DCs or for detection of apoptosis using the annexin V-FITC
apoptosis detection kit (BD PharMingen, San Diego, CA) on a FACSVantage SE (BD Biosciences). UV-irradiated (100 J/m2, UV Stratalinker 2400;
Stratagene, La Jolla, CA) syngeneic splenocytes were used as control apoptotic cells. Necrosis of B16-F1 cells was induced by four rapid cycles of
freeze/thaw, as evidenced by combined annexin V/propidium iodide (PI)
staining.
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thawed necrotic cells were also phagocytosed by DCs to a comparable extent as apoptotic cells (not shown). To rule out the
possibility of nonspecific tumor cell binding, coculture of apoptotic tumor and DCs was performed at 4°C; the percentage of double-positive cells was only 4% (Fig. 1F). DCs also efficiently
phagocytosed apoptotic syngeneic splenocytes (data not shown).
DCs loaded with apoptotic B16 cells migrate to lymph nodes
and up-regulate CD86 and MCH II expression
To induce a primary immune response, DCs have to undergo a
maturation process that involves up-regulation of MHC and co-

FIGURE 2. Phenotype of DCs before and after coculture with apoptotic B16 and migration into the
lymph nodes. A, Surface phenotype of DCs without
(DCs) and with (DC-Apo) coculture with apoptotic
B16 cells. The DCs and DC-Apo were stained with
PE-conjugated anti-CD11c, followed by FITC-conjugated anti-CD86 or MHC II (I-Ab). CD86 and MHC
II expression was evaluated on CD11c⫹-gated cells.
B, CD45.2⫹ DCs or CD45.2⫹ DC-Apo were injected
s.c into CD45.1⫹ mice. Twenty-four hours later,
draining lymph nodes were harvested, and single-cell
suspensions were obtained. Cells were then incubated
with allophycocyanin-conjugated anti-CD45.2, PEconjugated anti-CD11c, followed by FITC-conjugated anti-CD86 or MHC II. The expression of CD86
and MHC II was analyzed on CD45.2⫹, CD11c⫹gated cells, which were not found in uninjected
CD45.1⫹ mice. Gray lines show staining with isotype-matched control Abs. One representative experiment of three is shown.

DCs loaded with apoptotic B16 cells induce specific resistance
to B16 tumors including long term memory
To evaluate whether DCs cocultured with apoptotic B16 cells
(DC-Apo) were able to elicit resistance to challenge with tumor,
mice were vaccinated s.c. weekly for 4 wk with 2 ⫻ 105 DC-Apo
and challenged with 1.3 ⫻ 104 B16 cells 1 wk later. The efficiency
of vaccination by DC-Apo was compared with that in several other
types of DCs controls: DCs plus Apo without previous coculture
(DC⫹Apo), DCs alone, apoptotic tumor cells alone (Apo), DCs
cocultured with necrotic cells (DC-Nec), necrotic cells alone
(Nec), and vehicle (PBS; Fig. 3A). Also, to rule out the possibility
of a nonspecific activation by DCs phagocytosing apoptotic cells,
a group of mice that received DCs cocultured with syngeneic apoptotic splenocytes (DC-Spleen) was included. All mice were
monitored every other day after tumor challenge, and the tumor
volumes were measured.
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FIGURE 1. Apoptosis of irradiated B16 melanoma cells and phagocytosis by DCs. B16-F1 melanoma cells were cultured for 48 h, either untreated (A) or after irradiation (B), and stained with annexin V-FITC and
PI. Early apoptotic cells were defined as annexin V-FITC⫹, but PI⫺, while
necrotic cells were double-positive. To demonstrate phagocytosis (C–F),
DCs were labeled green with PKH67-GL fluorescent cell linker (C), and
apoptotic cells were labeled red with PKH26-GL (D); these were cultured
together at a 1/1 ratio for 24 h at 37°C (E) or 4oC (F). The frequency of
double-positive phagocytic DCs (gated as green profiles) is shown in the
upper right quadrants.

stimulatory molecules, and the DCs must also migrate to lymph
nodes to select infrequent naive T cell clones for activation. To
assess these attributes in our system, we cultured irradiated B16
cells for 24 h with DCs and double-stained with PE-anti-CD11c
and either FITC-anti-CD86 or FITC-anti-MHC II. While the expression of CD11c remained similar to that of DCs that were not
cultured with tumor cells, a large fraction of the tumor-exposed
DCs up-regulated CD86 as well as MHC II (Fig. 2A). We then
analyzed the migratory capacity of these cells. CD45.2⫹ DCs that
had been pulsed with apoptotic B16 cells or left unpulsed were
injected s.c. into CD45.1⫹ recipient mice. After 24 h the draining
lymph nodes were obtained, and the surface phenotype of the injected CD45.2⫹ cells was analyzed. CD11c⫹ cells from both tumor-pulsed and unpulsed DCs cultures were found in the draining
nodes, and both showed an up-regulation of CD86 and MHC II
molecules (Fig. 2B). The number of injected CD45.2⫹ cells in the
lymph nodes corresponded to ⬃0.5% of the administered inoculum, consistent with prior data (36). Therefore, a s.c. injection of
DCs, with or without exposure to apoptotic tumor, leads to the
residence of comparable, but small, numbers of mature DCs in the
draining lymph nodes, setting the stage for testing their immunizing capacity against B16 melanoma challenge.

The Journal of Immunology
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Both CD4⫹ and CD8⫹ T cells are required for the antitumor
response

FIGURE 3. Protection against tumor development after vaccination
with DCs loaded with apoptotic B16 melanoma. A, Mice (10 –13/group)
were vaccinated with DCs that had phagocytosed apoptotic tumor cells for
24 h (DC-Apo), DCs alone, apoptotic tumor cells alone (Apo), a mixture
of DCs and tumor cells (DC⫹Apo), DCs that had phagocytosed apoptotic
spleen cells (DC-Spleen), PBS, DCs that had phagocytosed necrotic B16
melanoma cells (DC-Nec), or necrotic tumor cells alone (Nec) weekly for
4 wk and challenged with 1.3 ⫻ 104 B16 cells 1 wk later. B, Mice (10/
group) were vaccinated with DC-Apo and challenged with either B16 or
EL-4 cells 1 wk after immunization. C, Mice (10/group) were vaccinated
with DC-Apo or PBS weekly for 4 wk and challenged 10 wk later with
1.3 ⫻ 104 B16 cells. In A–C, mice were monitored every other day for
tumor growth and were scored positive when tumors were palpable. One
representative experiment of three is shown.

We studied the role of CD4⫹ and CD8⫹ T cells in the observed
resistance to B16, which, as mentioned, has not previously been
shown to elicit combined CD4⫹ and CD8⫹ immunity in mice.
Mice vaccinated with DC-Apo received anti-CD4, anti-CD8, or
control rat IgG on the day before tumor challenge, followed by two
injections on days 0 and 1 after tumor challenge. In vivo depletion
of either CD4⫹ or CD8⫹ T cells by Ab treatment completely abrogated the protection from tumor challenge (Fig. 4). Since these
depletions were performed after DC-Apo vaccination, the results
suggest that both CD4⫹ and CD8⫹ T cells play a crucial role in
resistance to B16 melanoma following vaccination with DC-Apo.
DCs charged with apoptotic B16 efficiently prime both CD4⫹
and CD8⫹ T cells
To verify that both CD4⫹ and CD8⫹ T cells could be primed to
produce IFN-␥ after immunization with DC-Apo, CD4⫹ and
CD8⫹ T cells were purified by positive selection from spleens

Table I. Tumor-free survival after vaccination with DCs loaded with
apoptotic B16 melanomaa

Eighty percent of the mice vaccinated with DC-Apo remained
tumor-free 12 wk after challenge relative to 0% in the PBS controls (Fig. 3A). None of the control groups showed protection relative to the nonvaccinated animals. When mice were injected with
Apo only or with DC⫹Apo without previous coculture, only 8%
( p ⬍ 0.01) remained tumor-free at wk 12, indicating that DCs are
necessary to induce strong protection and that they need to be
previously cocultured with Apo. In mice injected with DCs only,
9% (p ⬍ 0.01) of the mice were tumor-free after 12 wk, ruling out
the possibility that tumor rejection was solely due to NK cell expansion, which can be induced by DCs (37–39) or to immunity in
response to culture medium proteins presented by DCs. It has been
shown that DCs cultured in the presence of FCS are capable of
inducing CD4⫹ T cell help (40, 41) and to prime CTLs more
efficiently than DCs cultured in FCS-free conditions (40). Therefore, the presence of FCS-derived peptides loaded onto the DCs

Expt.
No.

DC-Apo

DC

Apo

PBS

1
2
3

10/13 (77%)
8/10 (80%)
8/10 (80%)

1/11 (9%)
1/11 (9%)
1/10 (10%)

1/12 (8%)
1/12 (8%)
1/10 (10%)

0/12 (0%)
0/10 (0%)
0/10 (0%)

DC ⫹ Apo

DC-Nec

Nec

DC-Spleen

1/12 (8%)
1/11 (9%)

2/13 (15%)
2/11 (18%)

1/8 (12%)
2/11 (18%)

0/12 (0%)
0/12 (0%)

1
2

a
C57BL/6 mice were vaccinated s.c. with 2 ⫻ 105 DCs loaded with apoptotic B16
cells (DC-Apo), DCs alone, apoptotic tumor cells alone (Apo), a mixture of DCs and
tumor cells (DC ⫹ Apo), DCs that had phagocytosed apoptotic spleen cells (DCSpleen), PBS, DCs that had phagocytosed necrotic B16 melanoma cells (DC-Nec), or
necrotic tumor cells alone (Nec) weekly for 4 wk and challenged with 1.3 ⫻ 104 B16
cells 1 wk later. Results are presented as the number of tumor-free survivors over the
total number of animals 12 wk following tumor challenge.
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might have contributed to the observed antitumor response. When
mice were vaccinated with DCs loaded with syngeneic apoptotic
splenocytes, 0% remained tumor-free ( p ⬍ 0.01), indicating that
the induction of immunity was not due to a nonspecific activation
of DCs after phagocytosis of dying cells. In contrast to DC-Apo,
only 17% ( p ⬍ 0.01) of the mice injected with DC-Nec remained
tumor-free, demonstrating that Apo are a better source of Ag for
DCs priming. In summary, only mice vaccinated with DC-Apo
showed strong protection against the poorly immunogenic B16
melanoma (Table I).
To analyze the specificity of this antitumor response, mice vaccinated with DCs loaded with apoptotic B16 cells were challenged
with the EL-4 lymphoma, but all the mice developed tumor within
2 wk (Fig. 3B). This indicates that vaccination with DCs loaded
with apoptotic B16 cells induces a strong protection against B16
challenge, but does not protect against a nonrelated syngeneic
tumor.
To test whether vaccinated mice could acquire immunological
memory, mice were vaccinated with DC-Apo and challenged with
B16 10 wk later. Strong protection was again achieved after vaccination with DC-Apo. Twelve weeks after tumor challenge, 80%
of the mice remained tumor-free vs 0% of control mice ( p ⬍ 0.01;
Fig. 3C). These data indicate that DC-Apo vaccination imparts
considerable memory to B16.
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obtained from mice injected with DC-Apo or control mice 4 wk
after immunization. The T cell fractions were stimulated in vitro
for 48 h with intact B16 cells or with DCs that had been pretreated
with TRP-2 peptide or OVA-derived control peptide, and the medium was then assessed for the production of IFN-␥ (Fig. 5).
TRP-2 is a tissue differentiation Ag expressed by normal melanocytes and melanoma cells in both humans and mice (31, 42– 45)
and was used as a model tumor Ag. As shown in Fig. 5, only
CD8⫹ T cells from DC-Apo-vaccinated mice were able to respond
to intact B16 cells. However, both subsets responded to DC-TRP-2

FIGURE 5. CD4⫹ or CD8⫹ T cells are primed by DC-Apo to secrete
IFN-␥. CD4⫹ (A) or CD8⫹ (B) T cells were purified using MACS beads
from spleens obtained from DC-Apo-vaccinated or control mice 4 wk after
immunization. These cells were stimulated with intact B16 cells, DC-Apo,
DC pulsed with TRP-2 peptide, or DC pulsed with OVA peptide, as described in Materials and Methods. After 48 h culture supernatants were
harvested, and IFN-␥ release was measured by ELISA. No IFN-␥ was
produced by the PBS control mice (not shown). The mean ⫾ SD of triplicate determinations are shown.

In vivo cytotoxic effector activity induced after vaccination with
DC-Apo
To evaluate whether Ag-specific cytolytic activity could be detected in vivo following vaccination with DC-Apo, an in vivo cytotoxicity assay was performed. Syngeneic splenocytes were labeled with a high concentration of CFSE and loaded with the
TRP-2 peptide. These were coinjected i.v. with equal numbers of
non-TRP-2-loaded splenocytes, which were labeled with a lower
concentration of CFSE. The mice had been vaccinated with DCApo or DCs 4 wk earlier, and the spleens were harvested 10 h later
after injection of CFSEhigh and CFSElow cells. The specific cytolytic activity was measured by the disappearance of TRP-2-loaded
CFSEhigh target cells. No cytolytic activity was observed in mice
injected with DCs, but in mice injected with DC-Apo, the specific
cytolytic activity was 75% when 107 cells were transferred and
went up to 92% when 5 ⫻ 106 cells were transferred (Fig. 6). We
did not determine whether CD4⫹ or CD8⫹ T cells were responsible for this lytic activity, but nevertheless, our data indicate that
vaccination with DC-Apo leads to the production of effector T

FIGURE 6. In vivo cytolytic activity. CFSEhigh TRP-2180 –188-pulsed
splenocytes and equal numbers of CFSElow nonpulsed splenocytes were
coinjected i.v. into mice vaccinated with DC-Apo or DCs 4 wk after immunization. Ten hours later spleens were harvested, and in vivo cytolysis
of transferred cells was measured by the selective disappearance of the
TRP-2-loaded CFSEhigh cells. Specific lysis was calculated as described in
Materials and Methods.
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FIGURE 4. In vivo depletion of either CD4⫹ or CD8⫹ T cells ablates
protective antitumor immunity. Mice (10/group) were vaccinated on days
0, 7, 14, and 21 with DC-Apo or PBS. Vaccinated animals were divided
into groups treated with anti-CD4, anti-CD8, or normal rat IgG on days 27,
28, and 29. Then mice were challenged with 1.3 ⫻ 104 B16 cells on day
28. Mice were monitored every other day and were scored positive when
the tumors were palpable. One representative experiment of two is shown.

and DC-Apo, with the CD4⫹ T cell responses being more vigorous
(Fig. 5). As controls, CD8⫹ T cells from mice vaccinated with
DC-Apo made ⬍30 pg/ml without challenge or following challenge with DCs only or DC-OVA peptide (Fig. 5B). CD4⫹ T cells
from mice injected with DC-Apo also did not release IFN-␥ in the
absence of DCs, but did form small amounts of cytokine following
culture with DCs only or with DCs loaded with the control peptide
(Fig. 5A). Although these assays were performed using mouse serum, the DCs used as APCs had been cultured in 10% FCS, and the
presence of FCS-derived peptides could explain the control CD4⫹
T cell response observed against DC-OVA or DCs alone (40, 41).
T cells from control nonvaccinated mice made ⬍30 pg/ml of
IFN-␥ with or without challenge (data not shown). Our data indicate that IFN-␥-producing, TRP-2-specific, CD4⫹ and CD8⫹ T
cells are primed when mice are vaccinated with DCs loaded with
B16 melanoma.

The Journal of Immunology
cells that both secrete IFN-␥ (Fig. 5) and have cytolytic activity
(Fig. 6).

Discussion

were primed to produce IFN-␥ after restimulation with DCs loaded
with apoptotic B16 cells or DCs loaded with the TRP-2 melanoma
Ag (Fig. 5). In addition, the CD8⫹ cells were able to produce
IFN-␥ upon coculture with B16 melanoma cells, and the immunized mice were able to kill TRP-2-coated splenocytes in vivo
(Fig. 6). However, NK cells as well as other innate pathways, such
as phagocytes, NKT cells, and complement components, could
also contribute to the resistance that takes place in the presence of
tumor-specific T cells that are elicited by DC-Apo. In the results
reported by Hung et al. (33), the immune response induced by
vaccination with B16 cells engineered to secrete GM-CSF required
CD4⫹ T cells at the effector phase of the antitumor response. In
contrast, their data showed that depletion of CD8⫹ T cells only
partially reverted the protective response, suggesting that vaccination with B16:GM-CSF-secreting cells did not induce effective
CD8⫹ immunity. Similarly, Shibagaki et al. (32) showed that vaccination with B16:GM-CSF-secreting cells was relatively inefficient with regard to CTL and memory induction. Our data indicate
that DC-Apo have an advantage in eliciting combined helper and
cytotoxic T cell immunity.
Although the CD4⫹ helper cells did not recognize B16 melanoma cells directly, because the latter do not express MHC class II,
the immune CD4⫹ T cells did recognize DCs loaded with tumor
(Fig. 5). Ossendorp et al. (50) have previously shown that optimal
CTL induction requires cognate CD4⫹ T cell help even for MHC
class II-negative tumors. In that study the authors used a peptide
vaccination strategy to show that depletion of CD4⫹ T cells during
either the induction or effector phase of the immune response abrogates the survival of preimmunized mice. Likewise, Mumberg et
al. (51) showed that adoptively transferred CD4⫹ T cells eliminate
MHC class II-negative tumor cells in SCID mice. IFN-␥ was required, but it did not induce, MHC class II expression on the tumor, suggesting that tumor Ag were being cross-presented by
MHC class II⫹ host cells. Our data together with others (31, 33,
50) indicate that tumor-specific CD4⫹ T cells are required upon
tumor challenge for the effective antitumor response in immunocompetent mice. Such T cells may have several functions: to help
CD8⫹ T cell function in the draining lymph node, to contribute to
CTL infiltration into the tumor bed (52), to maintain in situ CTL
effector functions (53), to release factors that more directly provide
resistance against the tumor, i.e., IFN-␥ (54 –56), and/or to recruit
other effector cells (33).
We found that the TRP-2180 –188 peptide was recognized by both
CD4⫹ and CD8⫹ T cells. This peptide has been identified as a
relevant MHC class I (Kb) epitope (43, 44), but Wang et al. (31) have
reported that immunization with DCs loaded with TRP-2180 –188
peptide fused to a cell-penetrating peptide induce a CD4⫹ T cell
response as well, and that this is required for antitumor immunity, as
evidenced by CD4⫹ T cell depletion and the use of CD4⫹ knockout
mice. Peptides are known to bind to MHC class II molecules via a
nine amino acid core sequence (57–59), and this 9-aa core also is
recognized by the TCR (60). Therefore, the strong CD4 T cell
response to TRP-2 that we observed is not totally surprising.
When DCs are loaded with TRP-2 peptide only (using peptide
itself or a cell-penetrating fusion TRP-2 peptide, TRP-2 protein
transduction) and used to vaccinate mice against B16 melanoma,
the survival was found to be lower than that observed with B16:
GM-CSF-secreting cells, presumably because TRP-2 is but one of
many Ags in B16 cells (31–33). We also suspect that our use of
DC-Apo immunizes CD4⫹ or CD8⫹ T cells to many more B16
melanoma Ags than TRP-2, but these remain to be identified.
A perplexing finding in our study was that DCs loaded with
apoptotic cells, but not necrotic cells, were immunogenic, even
though both sources of dying cells were phagocytosed well by the
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DCs-based immunotherapy is being developed as a novel approach
to vaccination against cancer. DCs have the potential to be loaded
with a spectrum of tumor Ags and to prime both CD8⫹ and CD4⫹
T cells. However, the immune response to DCs loaded with different sources of tumor Ag requires investigation. In this study we
demonstrate that B16 melanoma cells undergoing apoptotic death
as a result of irradiation and culture are an effective source of Ag
for DCs-based vaccines, including the induction of both CD8⫹and CD4⫹-dependent, long-lived antitumor responses. The B16
melanoma model has been a valuable model for the study of tumor
immunity, but previous reports using apoptotic/necrotic cells to
load DCs (46, 47) have not documented combined CD4⫹ and
CD8⫹ dependent long term immunity.
In addition to being a source of tumor Ags for MHC class I and
II products, dying cells may influence the maturation state of the
DCs and thereby the quantity and quality of the ensuing immune
response. There are conflicting reports about whether apoptotic or
necrotic cells are capable of inducing DC maturation. Sauter et al.
(48) found that incubation of DCs with necrotic, but not apoptotic,
tumor cell lines induce maturation, while other reports concluded
that incubation with apoptotic cells is sufficient (25, 26, 46, 49).
Our results show that after coculture with gamma irradiation induced apoptotic B16 melanoma cells, a high proportion of DCs
phagocytose the apoptotic cells and up-regulate the expression of
CD86 and MHC class II molecules (Fig. 2A). However, it is possible that the presence of necrotic cells (⬍20%) in our apoptotic
cell preparation was relevant to the observed DCs maturation.
We also characterized the DCs that migrate to the draining
lymph nodes following s.c. injection, comparing DCs that had
been pulsed or not pulsed with apoptotic cells. The migrants uniformly expressed high levels of CD86 and MHC II molecules (Fig.
2B) comparable to fully mature and immunogenic DCs. However,
when we enumerated the migrating DCs only ⬃0.5% of the original inoculum was found in the draining lymph nodes 1 day after
injection.
Our current vaccine model uses four weekly injections of DCApo, and we have used this to prevent rather than treat B16 melanomas. Eighty percent of the mice remained tumor-free 12 wk
following challenge with B16 cells (Fig. 3A). No protection was
observed when DC-Apo-vaccinated mice were challenged with the
syngeneic EL-4 lymphoma (Fig. 3B), suggesting that the immune
response was directed against B16 melanoma Ag. Moreover, vaccination with DC-Apo induced immunological memory, since,
again, 80% of mice remained tumor-free when they received the
tumor challenge 10 wk after immunization (Fig. 3C). It will be
important to use DCs in the therapeutic setting, but at the tumor
cells doses we have used, large (⬃1-cm diameter) tumors are evident by 14 days, too quickly to study therapy. However, a critical
limitation in the current use of DC-Apo, as evident in Fig. 2B, is
the low number of migrating DCs 1 day after injecting 200,000
cells in each of the four paws, since a total of only ⬃4,000 DCs
were found in the draining lymph nodes. This suggests that with
current methods the injected DCs are functioning far below their
potential. This will need to be addressed to achieve strong T cell
immune responses and to approach therapeutic models.
When either CD4⫹ or CD8⫹ T cell subsets were depleted by Ab
treatment of vaccinated mice, the immune protection was completely abrogated, indicating that both T cell subsets were necessary for effective in vivo vaccination with DC-Apo (Fig. 4). In
vitro T cell assays also indicated that both CD4⫹ and CD8⫹ T cells
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DCs. Shimizu et al. (61), using lysates or peptide-pulsed DCs vaccines, reported that CD4⫹ T cell protection required the addition of
IL-2 and the addition of the immunogenic protein keyhole limpet
hemocyanin to the immunizing protocol. Kotera et al. (46) have
reported that DCs pulsed with highly enriched apoptotic or necrotic (lysates) B16 cells have equivalent antitumor activity, although their experiments were only followed for 18 days after
challenge, and the immunization conditions only allowed for a
delay in tumor growth. However, there are other examples showing that DCs loaded with apoptotic cells are more efficient than
DCs loaded with necrotic cells in activating T cells (24, 27, 62,
63). In the results reported by Albert et al. (27), Ag acquired from
apoptotic cells were efficiently cross-presented by DCs, while DCs
carrying Ag derived from necrotic cells were inefficient at inducing
CTLs. Strome et al. (62) found that DCs loaded with irradiated
tumor cells were effective stimulators of OVA-specific CTL clones
in vitro, whereas DCs loaded with freeze-thawed tumor cells failed
to stimulate IFN-␥ secretion. Furthermore, they reported an inhibitory effect of freeze-thawed tumor cells on the in vitro CTL activity. Similar results were observed when they used human melanoma cell lines and gp100-specific CTL clones. Then the authors
assessed the two Ag-loading strategies in vivo, and again only DCs
loaded with irradiated tumor cells were effective in preventing the
outgrowth of the OVA-expressing E.G7 thymoma. Schnurr et al.
(63) have found that DCs bearing apoptotic pancreatic tumor cells
were better suited than tumor-lysate-loaded DCs to activate both
CD8⫹ and CD4⫹ T cells in vitro. Using a squamous cell carcinoma model, Hoffmann et al. (24) have reported that apoptotic
cell-loaded DCs likewise induce stronger CTL responses compared with cell lysate-loaded DCs. Perhaps necrotic cell lysates are
adequate for loading DCs with tumor-associated Ags only when
the latter are more resistant to proteolysis or when the lysates provide additional stimulatory stimuli for the DCs.
Many studies have been conducted using dying tumor cells as a
source of Ags (22–26, 46, 62, 63). However, none of these has
shown in vivo induction of combined CD4⫹ and CD8⫹ antitumor
immunity. In the present study we found that DCs phagocytosing
apoptotic tumor cells elicit long-lived combined CD4⫹ and CD8⫹
immunity against the poorly immunogenic B16 melanoma. DCApo have been shown by Berard et al. (22) to be able to prime
naive human T cells in vitro to melanoma Ags. These findings
together with our preclinical model set the stage for comparable
studies in humans with DC-Apo as adjuvants for active immunization against cancer.
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